Get started
Author

Valentina Arena

Observed names: Arena V, Arena, Valentina
ORCID: 0000-0003-2782-2752
Observed ORCID: 0000-0003-2782-2752
OpenAlex ID: A5001754739
Up-front blinatumomab improves MRD clearance and outcome in adult Ph– B-lineage ALL: the GIMEMA LAL2317 phase 2 study
2025 · Renato Bassan, Sabina Chiaretti, et al. · Blood · 53
PDF
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia
2021 · Maria Cristina Puzzolo, Ilaria Del Giudice, et al. · Frontiers in Oncology · 35
PDF
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial
2023 · Sabina Chiaretti, Irene Della Starza, et al. · Blood · 32
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol
2022 · Monica Messina, Alfonso Piciocchi, et al. · Cancers · 27
PDF
Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations
2020 · Sara Raponi, Caterina Ilari, et al. · British Journal of Haematology · 25
PDF
Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial
2022 · Francesco Buccisano, Raffaele Palmieri, et al. · Haematologica · 23
PDF
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
2022 · Idanna Innocenti, Gianluigi Reda, et al. · Haematologica · 21
PDF
Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study
2021 · Gian Matteo Rigolin, Ilaria Del Giudice, et al. · Blood · 16
PDF
Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial
2024 · Adriano Venditti, Alfonso Piciocchi, et al. · Blood Advances · 14
PDF
Peripherally inserted central venous catheter for pediatric acute leukemia: A retrospective 11-year single-center experience
2023 · Silvio Ligia, Salvatore Giacomo Morano, et al. · The Journal of Vascular Access · 11
PDF
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol
2021 · Francesco Buccisano, Raffaele Palmieri, et al. · Blood Advances · 11
PDF
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group
2021 · Gian Matteo Rigolin, Francesco Cavazzini, et al. · Hematological Oncology · 11
PDF
Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)
2020 · Raffaele Palmieri, Alfonso Piciocchi, et al. · Blood · 11
Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients
2024 · Alfonso Piciocchi, Marta Cipriani, et al. · eJHaem · 10
PDF
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings
2022 · Sabina Chiaretti, Akram Taherinasab, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 10
High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study
2023 · Francesca R. Mauro, Irene Della Starza, et al. · Haematologica · 9
PDF
Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
2021 · Luciana Cafforio, Sara Raponi, et al. · Haematologica · 9
PDF
CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia
2021 · Raffaele Palmieri, Francesco Buccisano, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 6
Outcome of relapsed/refractory acute promyelocytic leukaemia in children, adolescents and young adult patients — a 25‐year Italian experience
2021 · Anna Maria Testi, Sara Mohamed, et al. · British Journal of Haematology · 6
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia
2025 · Lukas H. Haaksma, Raffaele Palmieri, et al. · Leukemia · 3
PDF
Childhood acute promyelocytic leukemia in a pediatric cancer referral center in Baghdad, Iraq. Improved results with ATRA extended consolidation
2022 · Anna Maria Testi, Mazin Faisal Al-Jadiry, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 3
Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia
2021 · Adriano Venditti, Alfonso Piciocchi, et al. · Blood · 3
Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia
2023 · Giovanni Marconi, Alfonso Piciocchi, et al. · Blood · 2
P432: Validation of Limit of Quantification Approach Based Flow Cytometry for Measurable Residual Disease Assessment in Acute Myeloid Leukemia in the Hovon-sakk-132 Trial
2023 · Jesse Tettero, Raffaele Palmieri, et al. · HemaSphere · 2
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia
2022 · Francesca Fazio, Gabriella Cunsolo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2
Works count: 45
Citation count: 355
H-index: 11
I10-index: 15
Year
Topic
Type